Open Access

REVIEW

ASPASIA MANTA¹, SPYRIDON KAZANAS², STEFANOS KARAMAROUDIS³, HELEN GOGAS², DIMITRIOS C. ZIOGAS^2,*
Oncology Research, Vol.30, No.5, pp. 211-219, 2022, DOI:10.32604/or.2022.026913
Abstract Epigenetic mechanisms, such as DNA methylation and histone modifications (e.g., acetylation and deacetylation), are strongly implicated in the carcinogenesis of various malignancies. During transcription, the expression and functionality of coding gene products are altered following the histone acetylation and deacetylation. These processes are regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. HDAC inhibitors (HDACis) have been developed as promising therapeutic agents, to limit exposure to traditional and toxic chemotherapies and offer more alternatives for some specific malignant diseases with limited options. Mechanistically, these agents affect many intracellular pathways, including cell cycle arrest, apoptosis and differentiation, and their mechanism… More >

View

871

Download

546

Like

1

Open Access

REVIEW

SUCHITRA NISHAL¹, VIKAS JHAWAT^1,*, SUMEET GUPTA², PARMITA PHAUGAT¹
Oncology Research, Vol.30, No.5, pp. 221-230, 2022, DOI:10.32604/or.2022.027549
Abstract Kinase inhibitors are a significant and continuously developing division of target therapeutics. The drug discovery and improvement efforts have examined numerous attempts to target the signaling pathway of kinases. The Kinase inhibitors have been heralded as a game-changer in cancer treatment. For developing kinase inhibitors as a treatment for various non-malignant disorders like auto-immune diseases, is currently undergoing extensive research. It may be beneficial to investigate whether cell-specific kinase inhibitor administration enhances therapeutic efficacy and decreases adverse effects. The goal of the current review is to gain insight into the role of kinase inhibitors in facilitating effective target drug delivery… More >

View

788

Download

292

Like

1

Open Access

REVIEW

JIATENG ZHONG^1,2, JINGYU GUO¹, XINYU ZHANG¹, SHUANG FENG¹, WENYU DI², YANLING WANG^3,*, HUIFANG ZHU^1,*
Oncology Research, Vol.30, No.5, pp. 231-242, 2022, DOI:10.32604/or.2022.027900
Abstract Lipid is a key component of plasma membrane, which plays an important role in the regulation of various cell biological behaviors, including cell proliferation, growth, differentiation and intracellular signal transduction. Studies have shown that abnormal lipid metabolism is involved in many malignant processes, including colorectal cancer (CRC). Lipid metabolism in CRC cells can be regulated not only by intracellular signals, but also by various components in the tumor microenvironment, including various cells, cytokines, DNA, RNA, and nutrients including lipids. In contrast, abnormal lipid metabolism provides energy and nutrition support for abnormal malignant growth and distal metastasis of CRC cells. In… More >

View

680

Download

424

Open Access

ARTICLE

LI YANG^1,2, KUN DENG³, ZHIQIANG MOU^1,2, PINGFU XIONG^1,2, JIAN WEN^1,2, JING LI^1,2,*
Oncology Research, Vol.30, No.5, pp. 243-258, 2022, DOI: 10.32604/or.2022.027958
Abstract Background: Considering the great heterogeneity of Hepatocellular carcinoma (HCC), more accurate prognostic models are urgently needed. This paper combined the advantages of genomics and pathomics to construct a prognostic model. Methods: First, we collected data from hepatocellular carcinoma patients with complete mRNA expression profiles and clinical annotations from the TCGA database. Then, based on immune-related genes, we used random forest plots to screen prognosis-related genes and build prognostic models. Bioinformatics was used to identify biological pathways, evaluate the tumor microenvironment, and perform drug susceptibility testing. Finally, we divided the patients into different subgroups according to the gene model algorithm. Pathological… More >

View

674

Download

457